Trial · NCT02408861
Adverse events1,337
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,337
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 1 | 6 | 3 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 0 | 9 | 0 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 1 | 7 | 1 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 0 | 4 | 0 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 3 | 24 | 3 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose Expansion Nivolumab 240 mg and Ipilimumab 1 mg/kg | 4 | 20 | 8 |
| other | ANEMIA | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Nivolumab 240 mg q2w in Classical Hodgkin Lymphoma | 1 | 9 | 2 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 0 | 6 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 0 | 9 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 0 | 7 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 0 | 4 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 0 | 24 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Dose Expansion Nivolumab 240 mg and Ipilimumab 1 mg/kg | 0 | 20 | 0 |
| other | BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHER, SPECIFY | BLOOD AND LYMPHATIC SYSTEM DISORDERS | Nivolumab 240 mg q2w in Classical Hodgkin Lymphoma | 1 | 9 | 1 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 1 | 6 | 1 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 0 | 9 | 0 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 0 | 7 | 0 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 0 | 4 | 0 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 0 | 24 | 0 |
| other | SINUS BRADYCARDIA | CARDIAC DISORDERS | Dose Expansion Nivolumab 240 mg and Ipilimumab 1 mg/kg | 0 | 20 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408861/events